Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2018

View Archived Issues

Chemical changes make arylomycins great against Gram-negatives

Zinc fingers go where CRISPR can't

Viva VIVO

White matter targeting improves TBI outcomes

Iterum announces the initiation of SURE 2 and SURE 3 phase III studies for sulopenem

Identification of a diagnostic gene signature in Kawasaki disease

Mechanisms of bacterial competition used by microbiota as a tool to develop new targeted antibiotics

Molecular Templates and Takeda enter agreement for joint development of CD38-targeted ETBs

Servier to use Poietis' 4D bioprinting technology for liver tissue

China Pharmaceutical University, Hefei Yigong Medicine describe new colchicine derivatives

Beijing Scitech-Mq Pharmaceuticals patents VEGFR-2 and HGFR inhibitors

Fujian Cosunter Pharmaceutical, Medshine Discovery divulge compounds for HBV infection

Neuronascent receives award to further develop NNI-362 for Alzheimer's

Apeiron Biologics and Lead Discovery Center to develop novel immune checkpoint modulators

Researchers present data for GSK-773 in myopathy

Preclinical profile of PI3K-delta inhibitor DS-1515 shows potential for treating asthma

Erytech begins phase III trial of eryaspase in second-line metastatic pancreatic cancer

Amygdala Neurosciences announces SEARCH phase II studies with ANS-6637

Oxurion initiates phase II study of THR-317 in macular telangiectasia type 1

Nanobiotix reports new data on NBTXR-3

Celltrion signs incubation agreement with Emory University to support atherosclerosis R&D

TAS-303 shows potential as a novel therapeutic agent for stress urinary incontinence

Mutations in ADPRHL2 linked to a degenerative pediatric stress-induced epileptic ataxia syndrome

RNF146 identified as novel therapeutic target in colorectal cancer

Immune system activation observed in phase I trial of AST-008